Ashley Buchanan, DrPH

  • Associate Professor
  • Office: 265A
  • Phone: 401.874.4739
  • Email:
  • Office Location: Avedisian Hall, 7 Greenhouse Road, Kingston, RI 02881



Dr. Ashley Buchanan is an Associate Professor of Biostatistics in the Department of Pharmacy Practice and Clinical Research in the College of Pharmacy at the University of Rhode Island, specializing in the areas of epidemiology and causal inference. She brings over fifteen years of experience collaborating on HIV/AIDS research, working closely with colleagues both domestically and internationally to develop and apply causal methodology to improve treatment and prevention of HIV/AIDS.

More recently, her substantive research area has expanded to studying opioid use disorder employing a variety of “big data” sources, including administrative claims data and prescription drug monitoring programs. Her current methodological research focuses on the development and application of causal inference methods for network studies of HIV treatment and prevention among marginalized populations that use illicit substances.


Causal inference; Generalizability; Interference/Dissemination; Network Science; Observational studies;  Longitudinal analysis; HIV/AIDS; Substance use disorder prevention and treatment; Opioid crisis  


Postdoctoral Research Fellow, Harvard T.H. Chan School of Public Health, 2016
DrPH, University of North Carolina at Chapel Hill, 2015
MS, Harvard University, 2007
BS, University of Massachusetts, Amherst, 2005

Selected Publications

Hernandez-Ramirez RU, Spiegelman D, Lok JJ, Forastiere L, Friedman SR, Latkin CA, Vermund SH, Buchanan AL. Evaluation of overall, direct, spillover, and composite effects of the components of a peer-driven intervention package on injection risk behavior among people who inject drugs in the HIV Prevention Trials Network 037 Study. AIDS and Behavior. Accepted, 2023.  

Buchanan AL, Katenka N, Lee Y, Wu J, Pantavou K, Friedman SR, Halloran ME, Brandon D. L. Marshall BDL, Forastiere L and Nikolopoulos GK. Methods for Assessing Spillover in Network-Based Studies of HIV/AIDS Prevention among People Who Use Drugs. Pathogens. 2023 Feb 15;12(2):326. 

Lee Y, Buchanan AL, Ogburn E, Friedman SR, Halloran M.E., Katenka N, Wu J, Nikolopoulos G. Finding influential subjects in a network using a causal framework. Biometrics. 2023 Dec;79(4):3715-3727. 

Aroke H, Buchanan AL, Katekna N, Crawford FW, Lee T, Halloran ME, Latkin C. Evaluating the mediating role of recall of intervention knowledge in the relationship between a peer-driven intervention and HIV risk behaviors among people who inject drugs. AIDS and Behavior. 2023 Feb;27(2):578-59. 

Sun T, Katenka N, Kogut S, Rich J, Bratberg J, Buchanan AL. Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States. Pharmacoepidemiology. 2022, 1(3), 101-112. 

Buchanan AL, Park, CJ, Bessey S, Goedel WC, Murray EJ, Friedman SR, Halloran ME, Katenka NV, Marshall BDL. Spillover effects of pre-exposure prophylaxis delivery for HIV prevention: Evaluating the importance of effect modification using an agent-based model. Epidemiology and Infection. 2022 Oct 28;150:e192. 

Lee T, Buchanan AL, Katenka N, Forastiere L, Halloran ME, Friedman S, Nikolopoulos G. Estimating causal effects of HIV prevention interventions with interference in network-based studies among people who inject drugs. Annals of Applied Statistics. In Press, 2022. 

Buchanan AL*, Sun T, Wu J, Aroke H, Bratberg B, Rich J, Kogut S, Hogan J. Toward evaluation of disseminated causal effects of medications for opioid use disorder within provider-based clusters using routinely-collected health data. Statistics in Medicine. 2022;41:3449–3465.  

Li F, Buchanan AL, and Cole SR. Generalizing trial evidence to target populations in non-nested designs: Applications to AIDS clinical trials. Journal of the Royal Statistical Society, Series C. In Press, 2022. 

Patry E, Upadhyay R, Bratberg JP, Buchanan AL, Matson KL. A Comparison of National, State, and Local Drug Use Surveys: The Youth Risk Behavior Survey and the Rx for Addiction and Medication Safety Program. R I Med J. 2022 Feb 1;105(1):20-25.  

Sun T, Aroke H, Kogut S, Katenka N, Bratberg J, Buchanan A. Early buprenorphine-naloxone initiation for opioid use disorder reduces opioid overdose, emergency room visits and healthcare cost compare to late initiation. The American Journal of Drug and Alcohol Abuse. 2022 Mar 4;48(2):217-25. 

Aroke, H., Katenka, N., Kogut, S., & Buchanan, A. (2021, November). Network-Based Analysis of Prescription Opioids Dispensing Using Exponential Random Graph Models (ERGMs). In International Conference on Complex Networks and Their Applications (pp. 716-730). Springer, Cham. 

Murray EJ, Marshall BDL, Buchanan AL. Emulating target trials to improve causal inference from agent-based models, American Journal of Epidemiology. 2021 Aug 1;190(8):1652-1658. 

Buchanan AL*, Bessey S, Goedel WC, King MRF, Murray EJ, Friedman SR, Halloran ME, Marshall BDL. Disseminated effects in agent based models: A potential outcomes framework to inform pre-exposure prophylaxis coverage levels for HIV prevention. American Journal of Epidemiology. 2021 May 4;190(5):939-948. 

Aroke HA, Buchanan AL, Bratberg JP, Hogan JW, Rich J, Wen X, Kogut SJ. Initial Patterns of Prescription Opioid Supply and Risk of Mortality Among Insured Adults in the United States. Journal of Addiction Medicine, 15(2), 99-108, 2021. 

Buchanan AL*, Vermund SH, Friedman SR, Spiegelman D. Assessing individual and disseminated effects in network-randomized studies. American Journal of Epidemiology. 187(11), 2449-2459, 2018. 

Buchanan AL*, Hudgens MG, Cole SR, Mollan KR, Sax PE, Daar ES, Adimora AA, Eron JJ, Mugavero MJ. Generalizing evidence from randomized trials using inverse probability of sampling weights. Journal of the Royal Statistical Society, Series A. 181(4), 1193-1209, 2018. 

Lesko CR, Buchanan AL, Westreich D, Edwards JK, Hudgens MG, Cole SR. Practical considerations when generalizing study results: A potential outcomes perspective. Epidemiology, 28(4), 553-561, 2017.